Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 10/20 | 0.43 |
| ▸ | THRB | P10828 | 10/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6862641 | 0.86 | SMN1; SMN2 (0.43) | THRATHRBOPRK1 | |
| SCHEMBL23983024 | 0.83 | THRA (0.60) | THRATHRB | |
| SCHEMBL27702907 | 0.82 | THRA (0.41) | THRATHRBOPRK1 | |
| SCHEMBL13399172 | 0.80 | THRA (0.45) | THRATHRBOPRK1 | |
| SCHEMBL3162305 | 0.78 | THRA (0.42) | THRATHRBOPRK1 | |
| SCHEMBL3162304 | 0.78 | THRA (0.54) | THRATHRBOPRK1 | |
| SCHEMBL6864350 | 0.78 | THRA (0.63) | THRATHRB | |
| SCHEMBL23003762 | 0.77 | THRB (0.66) | THRATHRB | |
| SCHEMBL6858246 | 0.77 | SMN1; SMN2 (0.46) | OPRK1 | |
| SCHEMBL27053517 | 0.75 | MEN1 (0.48) | THRATHRBOPRK1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286957-B1 | DIPHENYLMETHANE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-6803480-B2 | THERAPEUTIC TREATMENT AND/OR PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-10-12 | — | — | US | disclosed |
| US-20030203898-A1 | Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203898-A1 | Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia | APOB, HMGCR, PCSK9 | THRA 2817/4885THRB 2653/4885OPRK1 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.